|  |  |
| --- | --- |
| **Report title** | BAF and corporate risk register – Q1 2022/23 update |
| **Report from** | Company secretary |
| **Previously discussed at** | With individual risk owners, audit and risk committee |
| **Link to strategic objectives** | The corporate risk register and risk appetite statement links to all strategic objectives |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Brief** **summary of report**  The trust’s corporate risk register is the means by which the management executive holds itself to account and defends its patients and staff as well as the trust. It helps to clarify what risks are likely to compromise the trust’s strategic and operational objectives and assists the executive team in identifying where to make the most efficient use of their resources in order to improve the quality and safety of care. Along with the board assurance framework, this should support the creation of a culture which allows the organisation to anticipate and respond to adverse events, unwelcome trends and significant business and clinical opportunities. | | | | | | | |
| **Quality implications**  The trust must have a robust approach to risk management in order to maintain the highest standards of quality care provided to patients. Identification and mitigation of risk is an important tool in being able to manage events that could have an impact. | | | | | | | |
| **Financial implications**  There are no financial implications arising from this paper. | | | | | | | |
| **Risk implications**  As detailed in the paper. | | | | | | | |
| **Action Required/Recommendation.**  The board is asked to note the report and discuss risk updates. | | | | | | | |
| **For Assurance** | **✓** | **For decision** |  | **For discussion** | **✓** | **To note** |  |

**Board assurance framework executive summary report**

**April 2022 – June 2022 (Q1 2022/23)**

### BAF analysis and summary of changes

The top-rated risks to achieving the strategic objectives are as follows:

* 1. Impact of Covid-19 in all areas of the trust and on the wider system as a whole
  2. Delivery of our long-term plan for a new centre for research, education and clinical care
  3. Generation of sufficient commercial revenue
  4. Financial regime 22/23
  5. Recovery of clinical services
  6. Robust workforce planning
  7. Staff health and wellbeing
  8. Attraction of sufficient research funding
  9. Successful cyber-attack
  10. Digital infrastructure and resilience

All have been identified as risks that will have a significant impact on the delivery of patient care, the patient and staff experience, the financial sustainability and reputation of the trust or a combination of these. The identified areas are those that require the most focus from the Board in terms of scrutiny and provision of assurance from the executive team. Particular attention is also being given to those risks that are not wholly within the trust’s control to mitigate and a strategy developed as to how to manage such external factors.

* 1. ***Amendments made to the BAF this quarter***

The following risks have had their score reduced due to mitigating actions in place:

**Covid** risk from 4x4 (16) to 3x3 (9) and target score reduced from 4x2 (8) to 3x2 (6) – The silver command structure has been stood down, as the trust reverts to a BAU position. Proportionate IPC measures continue to remain in place and the score may reduce or be removed entirely in the next quarter.

**Research funding** risk from 5x3 (15) to 5x2 (10) – The score was reduced as the risk was not seen to be as high, the risk will be updated further in the next quarter.

**Recovery of clinical services** risk from 4x3 (12) to 4x2 (8) - The trust has made good progress in respect of recovery post-Covid-19, particularly in relation to patient follow ups but more work is required in relation to new patients.

* 1. ***Risks added to the BAF this quarter***

There were no risks added this quarter.

* 1. ***Risks removed from the BAF this quarter***

There were no risks removed this quarter.

***1.4 Emerging concerns from the corporate risk register***

The Q1 corporate risk register review has taken place and the following items have been escalated for consideration to be included on the risk register:

**CITO** – this continues to be monitored at directorate level and may be added in the next quarter

**Patient follow ups** – this is being reviewed and may be added in the next quarter

***1.5 Risks added to the corporate risk register***

One new risk has been added at Q1:

If the Trust is **unable to recruit a 'Named Doctor'** for paediatric safeguarding, then it will not be compliant with statutory requirements.